产品介绍：
产品说明
包装
10, 50 mg in glass bottle
生化/生理作用
Tiludronate is a bisphosphonate bone resorption inhibitor. Tiludronate inhibits protein-tyrosine-phosphatase, leading to detachment of osteoclasts from the bone surface. It also inhibits the osteoclastic proton pump and is used to treat Paget′s disease.
特点和优势
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
制备说明
Tiludronate disodium salt hydrate is soluble in DMSO at a concentration that is greater than or equal to 10 mg/ml.
基本信息
| 经验(实验)分子式 | C7H7ClNa2O6P2S · xH2O |
| 分子量 | 362.57 (anhydrous basis) |
| MDL编号 | MFCD16872037 |
| PubChem化学物质编号 | 329826798 |
| NACRES | NA.77 |
产品性质
| 质量水平 | 100 |
| 测定 | ≥98% (HPLC) |
| 形式 | powder |
| 储存条件 | desiccated |
| 颜色 | white to off-white |
| 溶解性 | H2O: >10 mg/mL, clear |
| 创始人 | Sanofi Aventis |
| SMILES string | O.[Na+].[Na+].OP([O-])(=O)C(Sc1ccc(Cl)cc1)P(O)([O-])=O |
| InChI | 1S/C7H9ClO6P2S.2Na.H2O/c8-5-1-3-6(4-2-5)17-7(15(9,10)11)16(12,13)14;;;/h1-4,7H,(H2,9,10,11)(H2,12,13,14);;;1H2/q;2*+1;/p-2 |
| InChI key | SZVJRJRMQCKFON-UHFFFAOYSA-L |
安全信息
| 储存分类代码 | 13 - Non Combustible Solids |
| WGK | WGK 3 |
| 闪点(F) | Not applicable |
| 闪点(C) | Not applicable |
